Ignite Creation Date:
2025-12-24 @ 9:27 PM
Ignite Modification Date:
2025-12-27 @ 11:08 AM
Study NCT ID:
NCT05222932
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-08-07
First Post:
2022-02-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
Sponsor:
TILT Biotherapeutics Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-03-08
Start Date Type:
ACTUAL
Primary Completion Date:
2026-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12
Completion Date Type:
ESTIMATED
First Submit Date:
2022-02-01
First Submit QC Date:
None
Study First Post Date:
2022-02-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-04
Last Update Post Date:
2025-08-07
Last Update Post Date Type:
ACTUAL